Bimekizumab for The Treatment of Psoriasis
Immunotherapy · 2024
DOI: 10.2217/imt-2023-0240 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunotherapy, 2024. Verfasst von Molly Thapar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 532261, USA. Hauptthemen laut MEDLINE: Th17 Cells, Psoriasis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben.
Abstract (Originalsprache)
Psoriasis is a chronic inflammatory skin condition characterized by Th17 T cell-mediated inflammation. An emerging treatment option for psoriasis is bimekizumab, a humanized monoclonal antibody targeting cytokines IL-17A and IL-17F. Phase I trials evaluating bimekizumab reported strong safety, tolerability, and clinical efficacy with most common treatment emergent adverse events being mild to moderate in nature. Phase II trials evaluated dosing intervals, revealing that higher dosages or more frequent administration of bimekizumab resulted in minimal increases in adverse events. Phase III trials and open label extension studies demonstrated a rapid, sustained clinical response when compared with placebo and active comparators. Bimekizumab shows strong efficacy in the treatment of psoriasis and has potential in the treatment of other Th17-mediated pathologies. Psoriasis is a chronic skin problem caused by the body's immune system. Bimekizumab, a new treatment, targets certain parts of the immune system involved in psoriasis. Studies testing bimekizumab in different phases showed it is safe and effective in treating psoriasis. Many patients taking bimekizumab had good results with mild side effects, and higher doses were well tolerated. When patients taking bimekizumab were followed for multiple years, the longitudinal study showed it worked well and continued to work. Bimekizumab works well for psoriasis but might help with similar immune-related conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 532261, USA.
- Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
ORCID-Profile: Molly Thapar, Kenneth Gordon
Zitieren
APA
Thapar, M., Patel, M., & Gordon, K. (2024). Bimekizumab for The Treatment of Psoriasis. Immunotherapy. https://doi.org/10.2217/imt-2023-0240
Vancouver
Thapar M, Patel M, Gordon K. Bimekizumab for The Treatment of Psoriasis. Immunotherapy. 2024. doi:10.2217/imt-2023-0240
BibTeX
@article{Thapar2024,
author = {Thapar, Molly and Patel, Milan and Gordon, Kenneth},
title = {Bimekizumab for The Treatment of Psoriasis},
journal = {Immunotherapy},
year = {2024},
doi = {10.2217/imt-2023-0240}
}
EUVIMED